Obviousness Analysis – PROMETHEUS LABORATORIES, INC. v. ROXANE LABORATORIES, INC.
The ‘770 patent which is owned by Prometheus Laboratories Inc., claims a method of treatment for IBS-D utilizing alosetron. Prometheus also has the ‘800 patent which covers the use of ‘770 patent. In 2009, Roxane filed an abbreviated new drug application (ANDA) with FDA seeking approval of a version of Lotronex, since the ‘770 patent…